1. Home
  2. PSFE vs LCTX Comparison

PSFE vs LCTX Comparison

Compare PSFE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysafe Limited

PSFE

Paysafe Limited

HOLD

Current Price

$8.52

Market Cap

390.7M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSFE
LCTX
Founded
1996
1990
Country
United Kingdom
United States
Employees
2900
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.7M
391.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PSFE
LCTX
Price
$8.52
$1.65
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$8.69
$5.33
AVG Volume (30 Days)
349.0K
992.3K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
$8.26
$109.40
Revenue Next Year
$6.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$5.95
$0.40
52 Week High
$16.49
$2.09

Technical Indicators

Market Signals
Indicator
PSFE
LCTX
Relative Strength Index (RSI) 73.09 56.12
Support Level $7.71 $1.56
Resistance Level $8.65 $1.82
Average True Range (ATR) 0.37 0.07
MACD 0.18 0.02
Stochastic Oscillator 95.39 85.11

Price Performance

Historical Comparison
PSFE
LCTX

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: